• Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

The two most pressing challenges facing humanity are the need to feed the growing population with restricted land and water sources and global warming caused due to high atmospheric CO2 levels. Biological systems for CO2 conversion to organic molecules using renewable-energy-harvesting techniques present a promising approach to simultaneously treating both problems. The lab of Prof. Ron Milo developed a breakthrough synthetic biology approach and engineered bacteria (E. coli) to consume CO2 as a source for their biomass carbon.


Background and Unmet Need

The two most pressing ecological challenges of our time are reducing CO2 levels in the atmosphere, which is responsible for extreme weather events and creating enough food for the ever-growing population. In light of the tremendous economic costs of global warming, there is a substantial economic incentive to develop new technologies capable of removing CO2 from the atmosphere. Importantly, today's food supply chain accounts for over 20% of anthropogenic greenhouse gasses emission1. Therefore, there is a growing need for developing a natural and sustainable food source. Biological systems for CO2 conversion to organic molecules present a promising avenue due to their high product specificity and modularity.

The Solution

Prof. Ron Milo and his team were the first ever to engineer E. coli bacteria to produce all of their biomass from CO2 as the sole carbon source2. Therefore, this technology can address both problems presented above at once: consuming CO2 for potentially synthesizing food3.

Technology Essence

Our engineered E. coli strain uses the Calvin cycle for carbon fixation and harvests energy and reducing power from the one-carbon molecule formate (HCOO?), which can be produced electrochemically.
The generation of a fully autotrophic E. coli required deleting central genes involved in carbon metabolism (Pfk A,B and Zwf), and expressing specific enzymes facilitating CO2 assimilation, namely Rubisco and phosphoribulokinase (Prk) for carbon fixation and formate dehydrogenase (FDH) for harvesting energy and reducing power from formate.
Heterologous expression of non-native enzymatic machinery potentially enables autotrophic growth; however, it does not guarantee that the cell will utilize it as a favorable pathway. To drive the flux toward the desired metabolic pathway, the deletions were implemented by rational design, and evolutionary pressure was used by growing cells in Xylose limited chemostats under continued starvation conditions in the presence of excess formate and CO2, to select cells with reduced dependence on external carbon source. Autotrophic growth was achieved following several months of continuous laboratory evolution and confirmed via isotopic labeling.
Figure 1: The experimental workflow begins from the left where the E. coli strain is engineered for xylose catabolism (pfkA, pfkB, Zwf deleted; Rubisco, Prk, CA, FDH overexpressed), but is unable to grow in autotrophic conditions. As the limited amount of xylose is consumed in the chemostat, and with an excess of formate and CO2, the cells are under a strong selection pressure to use CO2 as the only carbon source, while using formate oxidation by FDH as the energy source. Evolved clones with a fully autotrophic phenotype were then produced (right), as they achieved a fitness advantage over xylose dependent strains and become the dominant population in the chemostat.

Applications and Advantages

  • First ever central biotechnological heterotrophic organism switched to become autotrophic.
  • A potential modular platform for biotechnological production of various chemicals with net negative CO2 emissions, by integration of existing synthetic metabolic pathways into a synthetic autotrophic strain.
  • Assimilation of atmospheric CO2 with potential of cheap and facile production of high value products.
  • An E. coli line that can be further genetically engineered easily using standard tools.
  • Unique research tool to improve enzymes related to the CBB cycle to help in the production of more efficient plant/crop strains.

Development Status

The Milo team has performed the experimental work of generating novel strains of carbon fixing E. coli including characterization both in terms of carbon economy and genomic sequencing to determine the mutations leading to

E.coli autotrophy.

Poore J, Nemecek T. Reducing food's environmental impacts through producers and consumers. Science.
2018;360(6392):987-992. doi:10.1126/science.aaq0216
Gleizer S, Ben-Nissan R, Bar-On YM, et al. Conversion of Escherichia coli to Generate All Biomass Carbon from CO2. Cell. 2019;179(6):1255-1263.e1 doi:10.1016/j.cell.2019.11.009
Gleizer S, Bar-On YM, Ben-Nissan R, Milo R. Engineering Microbes to Produce Fuel, Commodities, and Food from CO2. Cell Rep Phys Sci. 2020;1(10):10022 doi:10.1016/j.xcrp.2020.100223

Intellectual property status

  • Granted Patent
  • Patent application number :PCT Published: Publication Number: WO2021/084526 USA Granted: 10,294,482

Related Keywords

  • Agriculture and Marine Resources
  • Agriculture
  • Precision agriculture
  • Other
  • Agricultural genetic engineering applications
  • bacteria

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support